[
    [
        {
            "time": "2021-04-20",
            "original_text": "晚间重要公告...恒瑞医药独立董事李援朝连任达六年，任期届满辞职...恒瑞医药股价跳水背后，销售费用畸高，十年行贿屡教难改引担忧...",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "独立董事辞职",
                    "销售费用畸高",
                    "股价跳水",
                    "行贿问题"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "晚间重要公告...恒瑞医药独立董事李援朝连任达六年，任期届满辞职...恒瑞医药股价跳水背后，销售费用畸高，十年行贿屡教难改引担忧...",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-04-20",
            "original_text": "恒瑞医药2020年营收、净利同比增长约两成，研发费用创新高...一季度业绩引发质疑...",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "营收增长",
                    "净利润增长",
                    "研发费用",
                    "业绩质疑"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "恒瑞医药2020年营收、净利同比增长约两成，研发费用创新高...一季度业绩引发质疑...",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-04-20",
            "original_text": "A股资金流向（4月20日）：新能源汽车板块遭抛售，光伏巨头获抢筹...",
            "features": {
                "keywords": [
                    "A股",
                    "资金流向",
                    "新能源汽车",
                    "光伏"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "新能源",
                    "光伏"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "A股资金流向（4月20日）：新能源汽车板块遭抛售，光伏巨头获抢筹...",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-04-20",
            "original_text": "山西证券：医药行业基本面良好，刚需带来确定性成长...",
            "features": {
                "keywords": [
                    "医药行业",
                    "基本面",
                    "刚需",
                    "确定性成长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "山西证券：医药行业基本面良好，刚需带来确定性成长...",
                "Correlation": 6,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-04-20",
            "original_text": "东莞证券：恒瑞医药抗肿瘤药物保持快增，维持“推荐”评级...",
            "features": {
                "keywords": [
                    "恒瑞医药",
                    "抗肿瘤药物",
                    "推荐评级"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "东莞证券：恒瑞医药抗肿瘤药物保持快增，维持“推荐”评级...",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]